Fly­ing so­lo for a change, Sanofi says isat­ux­imab scored an im­por­tant suc­cess in first PhI­II myelo­ma study

Maybe Sanofi can de­vel­op a ma­jor new on­col­o­gy drug on its own.

Ear­ly Tues­day the phar­ma gi­ant an­nounced the suc­cess­ful — topline — Phase III out­come …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA